Data set II: Proteome and phosphoproteome in CPTAC ovarian cancer cohort

In the second case study, we visualize high-grade serous ovarian carcinoma data from mass spectrometry-based untargeted proteomics and phosphoproteomics experiments conducted by the Clinical Proteomics Tumor Analysis Consortium (CPTAC). Our visualization follows that of Zhang et al22. In their analysis, the authors retained the 3586 proteins out of the 9600 that were quantified in 169 tumors. For the phosphoproteome data, the authors quantified the relative abundance for 69 tumor samples. Among these, 67 samples were quantified at both omics level and were used in the final visualization. Phosphosites with more than 50% of missing data were filtered out and the remaining missing values were imputed using KNNImpute64. Since ischemia of the TCGA tumor samples was found to be a confounding variable that altered phosphopeptide abundance, phosphosites that were shown to be regulated in ovarian carcinoma65 were also removed. The abundances were converted to z-scores before visualizing in multiSLIDE. A total of 16718 kinase-substrate interactions were curated from PhosphoSitePlus31, PhosphoNetworks32 and a predictive network inference approach33 to build the kinase-substrate map.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.